RxDoctor Payments Data

Kian Ehsan, MD

Interventional Cardiology · Lafayette, LANPI 1639349921

Payments from drug & device makers

$6,070in general payments, 2019–2025

Across 118 payments — averaging $51.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Medtronic$744
  • Abiomed$545
  • Novartis$241
  • Johnson & Johnson$201
  • Boston Scientific$142
  • plus $748 from 15 others

What the payments were for

  • Travel & lodging$2,88848%
  • Food & beverage$3,06050%
  • Other$1222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,070 in reported general payments places this provider in the 30th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$856,630
Medicare patients
1,863
Services billed
8,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban517$387,139
EliquisApixaban431$328,076
FarxigaDapagliflozin Propanediol131$97,799
EntrestoSacubitril/Valsartan119$86,376
BrilintaTicagrelor108$57,573
Repatha SureclickEvolocumab88$54,175
WegovySemaglutide20$26,313
OzempicSemaglutide22$20,242
Ranolazine ErRanolazine381$18,992
NexletolBempedoic Acid22$10,777
Losartan Potassium1,163$9,115
Rosuvastatin Calcium618$7,287
Amlodipine Besylate1,542$6,496
Pravastatin Sodium474$5,557
Midodrine Hcl124$5,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$201$387,139517 claims
AstraZenecaFarxiga, Brilinta$21$155,372239 claims
NovartisEntresto$241$86,376119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →